Menu
 
Research menu
Jump to menu

Publications:  Prof Frances Balkwill

Bast RC, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL et al.(2019). Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer vol. 125, (12) 1963-1972.
10.1002/cncr.32004
Boven E(2018). The Nude Mouse in Oncology Research. CRC Press
McDermott JR, Jones R, Lockley M, Balkwill FR (2017). The Chemokine CXCL10 is a Potential Regulator of Cancer Stem Cells in High Grade Serous Carcinoma. JOURNAL OF PATHOLOGY. vol. 243, S15-S15.
Netea MG, Balkwill F, Chonchol M, Cominelli F, Donath MY, Giamarellos-Bourboulis EJ, Golenbock D, Gresnigt MS et al.(2017). A guiding map for inflammation. Nat Immunol vol. 18, (8) 826-831.
10.1038/ni.3790
McCarthy FM, Candido J, Rudd R, Steele JPC, Balkwill F (2017). Upregulation of amphiregulin on CD14++CD16-(classical) monocytes in non-small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY. vol. 35,
10.1200/JCO.2017.35.15_suppl.e14612
Walton J, Blagih J, Ennis D, Leung E, Dowson S, Farquharson M, Tookman LA, Orange C et al.(2016). CRISPR/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high-grade serous carcinoma. Cancer Research vol. 76, (20) 6118-6129.
10.1158/0008-5472.CAN-16-1272
Delaine-Smith RM, Burney S, Balkwill FR, Knight MM(2016). Experimental validation of a flat punch indentation methodology calibrated against unconfined compression tests for determination of soft tissue biomechanics. Journal of the Mechanical Behavior of Biomedical Materials vol. 60, 401-415.
10.1016/j.jmbbm.2016.02.019
Steele CW, Karim SA, Leach JDG, Bailey P, Upstill-Goddard R, Rishi L, Foth M, Bryson S et al.(2016). CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. Cancer cell vol. 29, (6) 832-845.
10.1016/j.ccell.2016.04.014
Kulbe H, Iorio F, Chakravarty P, Milagre CS, Moore R, Thompson RG, Everitt G, Canosa M et al.(2016). Integrated transcriptomic and proteomic analysis identifies protein kinase CK2 as a key signaling node in an inflammatory cytokine network in ovarian cancer cells. Oncotarget vol. 7, (13)
10.18632/oncotarget.7255
Walton J, Dowson S, Ennis D, Leung E, Farquharson M, Stevenson D, Blyth K, Strathdee D et al.(2016). CRISPR/Cas9 mediated p53 and BRCA2 knockout to generate improved murine models of high grade serous ovarian cancer. CLINICAL CANCER RESEARCH vol. 22,
10.1158/1557-3265.OVCA15-B53
Crusz SM, Balkwill FR(2015). Inflammation and cancer: Advances and new agents. Nature Reviews Clinical Oncology vol. 12, (10) 584-596.
10.1038/nrclinonc.2015.105
Bowtell DD, Böhm S, Ahmed AA, Aspuria P-J, Bast RC, Beral V, Berek JS, Birrer MJ et al.(2015). Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nature Reviews Cancer vol. 15, (11) 668-679.
10.1038/nrc4019
Balkwill F, Chambers K(2015). Centre of the Cell: Science Comes to Life. PLOS BIOLOGY vol. 13, (9) Article ARTN e1002240,
10.1371/journal.pbio.1002240
Montfort A, Boehm S, Dowe T, Topping J, Lockley M, Capasso M, Balkwill F (2015). B cells actively participate to the anti-cancer immune response in high grade serous ovarian cancer metastases. CANCER RESEARCH. vol. 75,
10.1158/1538-7445.AM2015-455
Milagre CS, Gopinathan G, Everitt G, Thompson RG, Kulbe H, Zhong H, Hollingsworth RE, Grose R et al.(2015). Adaptive upregulation of EGFR limits attenuation of tumor growth by neutralizing IL6 antibodies, with implications for combined therapy in ovarian cancer. Cancer Research vol. 75, (7) 1255-1264.
10.1158/0008-5472.CAN-14-1801
Balkwill F(2015). Targeting inflammatory cytokines in cancer. CLINICAL & EXPERIMENTAL METASTASIS vol. 32, (3) 183-183.
Affara NI, Ruffell B, Johansson M, Fujikawa K, Bergsland E, DeNardo DG, Chen HI, Wadhwani N et al.(2014). Abstract 4391: CD20 as a target for therapy in solid tumors. Immunology
10.1158/1538-7445.am2012-4391
Kulbe H, Chakravarty P, Moore R, Iorio F, Montoya A, Saez-Rodriguez J, Cutillas P, Balkwill F(2014). Abstract 49: Targeting the TNF network in human ovarian cancer - A systems biology approach. Molecular and Cellular Biology
10.1158/1538-7445.am2012-49
Coward J, Kulbe H, Leader D, Quigley M, Leinster DA, Thompson R, Nemeth J, Vermeulen J et al. (2010). Abstract 5331: Interleukin-6 as a therapeutic target in advanced ovarian cancer. Clinical Research. Conference: Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC
10.1158/1538-7445.am10-5331
Balkwill F (2014). Targeting inflammatory cytokines in cancer. CYTOKINE. vol. 70, 21-21.
10.1016/j.cyto.2014.07.224
Rei M, Gonçalves-Sousa N, Lança T, Thompson RG, Mensurado S, Balkwill FR, Kulbe H, Pennington DJ et al.(2014). Murine CD27(-) Vγ6(+) γδ T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages. Proc Natl Acad Sci U S A vol. 111, (34) E3562-E3570.
10.1073/pnas.1403424111
Balkwill F(2014). Targeting cancer-related inflammation. EUROPEAN JOURNAL OF CANCER vol. 50, S9-S9.
10.1016/S0959-8049(14)50033-0
Karin M, Jobin C, Balkwill F(2014). Chemotherapy, immunity and microbiota--a new triumvirate?. Nat Med vol. 20, (2) 126-127.
10.1038/nm.3473
Lau T-S, Chung TK-H, Cheung T-H, Chan LK-Y, Cheung LW-H, Yim S-F, Siu NS-S, Lo K-W et al.(2014). Cancer cell-derived lymphotoxin mediates reciprocal tumour-stromal interactions in human ovarian cancer by inducing CXCL11 in fibroblasts. J Pathol vol. 232, (1) 43-56.
10.1002/path.4258
Rei M, Lanca T, Thompson R, Balkwill F, Silva-Santos B, Pennington DJ (2013). Major contribution of gamma delta T cells to IL-17A production and ovarian cancer cell growth in vivo. IMMUNOLOGY. vol. 140, 160-160.
Whilding LM, Archibald KM, Kulbe H, Balkwill FR, Öberg D, McNeish IA(2013). Vaccinia virus induces programmed necrosis in ovarian cancer cells. Mol Ther vol. 21, (11) 2074-2086.
10.1038/mt.2013.195
Boehm S, Ennis D, Dowe T, Canosa M, McNeish I, Lockley M, Balkwill F (2013). Tumour-associated inflammatory cytokines are reduced following primary platinum-based chemotherapy in plasma of high-grade serous ovarian cancer patients. EUROPEAN JOURNAL OF CANCER. vol. 49, S736-S736.
Sandhu SK, Papadopoulos K, Fong PC, Patnaik A, Messiou C, Olmos D, Wang G, Tromp BJ et al.(2013). A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemother Pharmacol vol. 71, (4) 1041-1050.
10.1007/s00280-013-2099-8
Balkwill F, Montfort A, Capasso M(2013). B regulatory cells in cancer. Trends Immunol vol. 34, (4) 169-173.
10.1016/j.it.2012.10.007
Balkwill FR, Capasso M, Hagemann T(2012). The tumor microenvironment at a glance. J Cell Sci vol. 125, (Pt 23) 5591-5596.
10.1242/jcs.116392
Balkwill F (2012). Targeting Cytokine Networks in Malignancy. EUROPEAN JOURNAL OF CANCER. vol. 48, S10-S10.
10.1016/S0959-8049(12)70746-3
Leinster DA, Kulbe H, Everitt G, Thompson R, Perretti M, Gavins FNE, Cooper D, Gould D et al.(2012). The peritoneal tumour microenvironment of high-grade serous ovarian cancer. J Pathol vol. 227, (2) 136-145.
10.1002/path.4002
Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN et al.(2012). Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med vol. 366, (7) 610-618.
10.1056/NEJMoa1110352
Balkwill FR, Mantovani A(2012). Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol vol. 22, (1) 33-40.
10.1016/j.semcancer.2011.12.005
Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, Coward JI, Schioppa T et al.(2012). A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res vol. 72, (1) 66-75.
10.1158/0008-5472.CAN-11-2178
Balkwill FR(2012). The chemokine system and cancer. J Pathol vol. 226, (2) 148-157.
10.1002/path.3029
Balkwill FR, Coward J, Kulbe H, Milagre C, Gopinathan G, McNeish IA(2011). IL-6 and ovarian cancer--response. Clin Cancer Res vol. 17, (24)
10.1158/1078-0432.CCR-11-2680
Rei M, Lanca T, King E, Kulbe H, Balkwill F, Silva-Santos B, Pennington DJ (2011). Understanding the dual role of murine gamma delta T cells in tumour surveillance and tumour progression. IMMUNOLOGY. vol. 135, 146-146.
Balkwill F (2011). Inflammatory cytokines and autocrine tumour-promoting networks. CYTOKINE. vol. 56, 51-51.
10.1016/j.cyto.2011.07.338
Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC et al.(2011). Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer vol. 11, (10) 719-725.
10.1038/nrc3144
Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, Thompson R, Schioppa T et al.(2011). Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res vol. 17, (18) 6083-6096.
10.1158/1078-0432.CCR-11-0945
Balkwill F, Whitehead S, Willis P, Gaymond N, Kent A, Page C, Lovell-Badge R, Morris R et al.(2011). Safety of medicines and the use of animals in research. Lancet vol. 378, (9786) 127-128.
10.1016/S0140-6736(11)60984-7
Schioppa T, Moore R, Thompson RG, Rosser EC, Kulbe H, Nedospasov S, Mauri C, Coussens LM et al.(2011). B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis. Proc Natl Acad Sci U S A vol. 108, (26) 10662-10667.
10.1073/pnas.1100994108
Balkwill F (2011). INFLAMMATORY CYTOKINES AND AUTOCRINE TUMOR-PROMOTING NETWORKS. INFLAMMATION RESEARCH. vol. 60, 26-26.
Allan S, Balkwill F(2011). Translating science in more ways than one: an interview with Frances Balkwill. DIS MODEL MECH vol. 4, (3) 286-288.
10.1242/dmm.007898
Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, Power J, Coward J et al.(2011). IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res vol. 17, (8) 2538-2548.
10.1158/1078-0432.CCR-10-3314
Salako MA, Kulbe H, Ingemarsdotter CK, Pirlo KJ, Williams SL, Lockley M, Balkwill FR, McNeish IA(2011). Inhibition of the inflammatory cytokine TNF-α increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression. Mol Ther vol. 19, (3) 490-499.
10.1038/mt.2010.247
Balkwill F (2011). MECHANISMS OF THE TUMOR-PROMOTING ACTION OF TNF-alpha IN EPITHELIAL TUMORS. ADVANCES IN TNF FAMILY RESEARCH. Editors: Wallach, D, Kovalenko, A, Feldman, M, vol. 691, 653-654.
Schioppa T, Moore R, Thompson R, de Visser K, Coussens LM, Balkwill F (2011). ROLE OF B CELL IN TWO-STAGE SKIN CARCINOGENESIS. ADVANCES IN TNF FAMILY RESEARCH. Editors: Wallach, D, Kovalenko, A, Feldman, M, vol. 691, 755-756.
Balkwill F (2010). Inflammatory cytokines and autocrine tumor-promoting networks. IMMUNOLOGY. vol. 131, 3-3.
Balkwill F, Joffroy C(2010). TNF: a tumor-suppressing factor or a tumor-promoting factor?. Future Oncol vol. 6, (12) 1833-1836.
10.2217/fon.10.155
Coward J, Balkwill F(2010). Targeting Inflammatory Pathways in Epithelial Ovarian Cancer. Emerging Therapeutic Targets in Ovarian Cancer, Springer New York
Balkwill F(2010). The Inflammatory Tissue Microenvironment and the Early Stages of Malignancy. Pre-Invasive Disease: Pathogenesis and Clinical Management, Springer New York
Toulza F, Nosaka K, Tanaka Y, Schioppa T, Balkwill F, Taylor GP, Bangham CRM(2010). Human T-lymphotropic virus type 1-induced CC chemokine ligand 22 maintains a high frequency of functional FoxP3+ regulatory T cells. J Immunol vol. 185, (1) 183-189.
10.4049/jimmunol.0903846
Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J et al.(2010). Guidelines for the welfare and use of animals in cancer research. Br J Cancer vol. 102, (11) 1555-1577.
10.1038/sj.bjc.6605642
Coward JI, Kulbe H, Leader D, Quigley M, Thompson R, Leinster A, Nemeth J, Vermeulen J et al. (2010). Interleukin-6 as a therapeutic target in advanced ovarian cancer. JOURNAL OF CLINICAL ONCOLOGY. vol. 28,
10.1200/jco.2010.28.15_suppl.5089
Forster MD, Patnaik A, Sandhu SK, Papadopoulos K, Tromp BJ, Messiou C, Balkwill F, Berns B et al. (2010). Pre-final analysis of first-in-human, first-in-class, phase I clinical trial of CNTO 888, a human monoclonal antibody to the CC-chemokine ligand 2 (CCL2) in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. vol. 28, 2548-2548.
10.1200/jco.2010.28.15_suppl.2548
Balkwill F, Mantovani A(2010). Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther vol. 87, (4) 401-406.
10.1038/clpt.2009.312
Saadi A, Shannon NB, Lao-Sirieix P, O'Donovan M, Walker E, Clemons NJ, Hardwick JS, Zhang C et al.(2010). Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc Natl Acad Sci U S A vol. 107, (5) 2177-2182.
10.1073/pnas.0909797107
Balkwill F, Mantovani A(2010). Foreword. Cytokine Growth Factor Rev vol. 21, (1)
10.1016/j.cytogfr.2009.11.004
Sandhu SK, Fong PC, Patnaik A, Papadopoulos K, Messiou C, Hoare S, Olmos D, Tromp BJ et al. (2009). First-in-man, first-in-class, pharmacokinetic and pharmacodynamic phase I clinical trial of a human monoclonal antibody CNT0888 to CC-chemokine ligand 2 (CCL2) / monocyte chemoattractant protein (MCP-1) in patients with advanced solid tumors. MOLECULAR CANCER THERAPEUTICS. vol. 8,
10.1158/1535-7163.TARG-09-A102
Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, Schultheis A, Chakravarty P, Thompson RG et al.(2009). The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest vol. 119, (10) 3011-3023.
10.1172/JCI39065
Kwong J, Kulbe H, Wong D, Chakravarty P, Balkwill F(2009). An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells. Mol Cancer Ther vol. 8, (7) 1893-1905.
10.1158/1535-7163.MCT-08-0966
Kwong J, Chan FL, Wong K-K, Birrer MJ, Archibald KM, Balkwill FR, Berkowitz RS, Mok SC(2009). Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells. Neoplasia vol. 11, (6) 529-541.
10.1593/neo.09112
Coward J, Quigley M, Leader D, Berns B, Balkwill F, McNeish I(2009). A Phase II study of intravenous CNT0328 in patients with recurrent epithelial ovarian cancer. CANCER RESEARCH vol. 69,
Kulbe H, Leinster A, Chakravarty P, Kwong J, Thompson R, Schioppa T, Coward J, Hagemann T et al. (2009). An autocrine cytokine network in ovarian cancer that influences patient survival. CANCER RESEARCH. vol. 69,
Balkwill FR (2009). CHEMOKINE RECEPTORS AND INFLAMMATION IN CANCER. ANNALS OF ONCOLOGY. vol. 20, 17-17.
Schioppa T, Moore R, Thompson R, de Visser K, Coussens L, Balkwill F(2009). Role of B cell in two-stage skin carcinogenesis. CANCER RESEARCH vol. 69,
Archibald K, Kwong J, Kulbe H, Young B, Balkwill F(2009). Spontaneously transformed hTERT immortalized human ovarian surface epithelial cells have a functional amplification of the CXCR4 gene locus. CANCER RESEARCH vol. 69,
Balkwill F(2009). Tumour necrosis factor and cancer. Nat Rev Cancer vol. 9, (5) 361-371.
10.1038/nrc2628
Li NF, Kocher HM, Salako MA, Obermueller E, Sandle J, Balkwill F(2009). A novel function of colony-stimulating factor 1 receptor in hTERT immortalization of human epithelial cells. Oncogene vol. 28, (5) 773-780.
10.1038/onc.2008.412
Brown ER, Charles KA, Hoare SA, Rye RL, Jodrell DI, Aird RE, Vora R, Prabhakar U et al.(2008). A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. ANN ONCOL vol. 19, (7) 1340-1346.
10.1093/annonc/mdn054
Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, Robinson SC, Balkwill FR(2008). "Re-educating" tumor-associated macrophages by targeting NF-kappaB. J Exp Med vol. 205, (6) 1261-1268.
10.1084/jem.20080108
Ashworth A, Balkwill F, Bast RC, Berek JS, Kaye A, Boyd JA, Mills G, Weinstein JN et al.(2008). Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. GYNECOL ONCOL vol. 108, (3) 652-657.
10.1016/j.ygyno.2007.11.014
Harrison ML, Obermueller E, Maisey NR, Hoare S, Edmonds K, Li NF, Chao D, Hall K et al. (2007). Tumor necrosis factor alpha as a new target for renal cell carcinoma: Two sequential phase II trials of infliximab at standard and high dose. JOURNAL OF CLINICAL ONCOLOGY. vol. 25, 4542-4549.
10.1200/JCO.2007.11.2136
Li NF, Broad S, Lu YJ, Yang JS, Watson R, Hagemann T, Wilbanks G, Jacobs I et al.(2007). Human ovarian surface epithelial cells immortalized with hTERT maintain functional pRb and p53 expression. Cell Prolif vol. 40, (5) 780-794.
10.1111/j.1365-2184.2007.00462.x
Hagemann T, Balkwill F, Lawrence T(2007). Inflammation and cancer: A double-edged sword. CANCER CELL vol. 12, (4) 300-301.
10.1016/j.ccr.2007.10.005
Balkwill FR, Ward BG, Fiers W(2007). Effects of Tumour Necrosis Factor on Human Tumour Xenografts in Nude Mice. 154-169.
10.1002/9780470513521.ch11
Lawrence T, Hageman T, Balkwill F(2007). Cancer. Sex, cytokines, and cancer. Science vol. 317, (5834) 51-52.
10.1126/science.1146052
Szlosarek PW, Grimshaw MJ, Wilbanks GD, Hagemann T, Wilson JL, Burke F, Stamp G, Balkwill FR(2007). Aberrant regulation of argininosuccinate synthetase by TNF-alpha in human epithelial ovarian cancer. Int J Cancer vol. 121, (1) 6-11.
10.1002/ijc.22666
Hagemann T, Robinson SC, Thompson RG, Charles K, Kulbe H, Balkwill FR(2007). Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Mol Cancer Ther vol. 6, (7) 1993-2002.
10.1158/1535-7163.MCT-07-0118
Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, Gould D, Ayhan A et al.(2007). The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. CANCER RES vol. 67, (2) 585-592.
10.1158/0008-5472.CAN-06-2941
Lawrence T, Fong C, Bebien M, Karin M, Balkwill F, Hagemann T (2007). IKKbeta inhibits 'Classical' macrophage activation in innate immunity and cancer. JOURNAL OF LEUKOCYTE BIOLOGY. 41-41.
Szlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Smith P, Crook T, Grimshaw MJ, Steele JP et al.(2006). In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. CLIN CANCER RES vol. 12, (23) 7126-7131.
10.1158/1078-0432.CCR-06-1101
Direkze NC, Jeffery R, Hodivala-Dilke K, Burke F, Hunt FT, Poulsom R, Balkwill F, Wright NA et al. (2006). Bone marrow contributes to functionally active cells in tumour stroma. JOURNAL OF PATHOLOGY. vol. 210, 1-1.
Balkwill F(2006). TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev vol. 25, (3) 409-416.
10.1007/s10555-006-9005-3
Strauss SJ, Maharaj L, Hoare S, Johnson PW, Radford JA, Vinnecombe S, Millard L, Rohatiner A et al.(2006). Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol vol. 24, (13) 2105-2112.
10.1200/JCO.2005.04.6789
Hagemann T, Wilson J, Burke F, Kulbe H, Li NF, Plüddemann A, Charles K, Gordon S et al.(2006). Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol vol. 176, (8) 5023-5032.
10.4049/jimmunol.176.8.5023
Hagemann T, Wilson J, Burke F, Kulbe H, Li NF, Pluddemann A, Charles K, Gordon S et al.(2006). Ovarian cancer cells polarize macrophages towards a tumor-associated phenotype. MED KLIN vol. 101, (4) A44-A44.
Balkwill F(2006). Cancer and inflammation. EUR J CANCER vol. 42, (6) 689-690.
10.1016/j.ejca.2006.03.002
Szlosarek P, Charles KA, Balkwill FR(2006). Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer vol. 42, (6) 745-750.
10.1016/j.ejca.2006.01.012
Balkwill FR, Ashworth A, Bast RC, Berek JS, Boyd J, Disis ML, Gabra H, Gore ME et al.(2006). 10th Biennial Helene Harris Memorial Trust meeting. Cancer Res vol. 66, (6) 2904-2906.
10.1158/0008-5472.CAN-05-2093
Balkwill F(2006). Inflammation: a double-edged sword. EUR J CANCER vol. 42, (5) 571-571.
Szlosarek PW, Grimshaw MJ, Kulbe H, Wilson JL, Wilbanks GD, Burke F, Balkwill FR(2006). Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium. MOL CANCER THER vol. 5, (2) 382-390.
10.1158/1535-7163.MCT-05-0303
Kulbe H, Hagemann T, Szlosarek PW, Balkwill FR, Wilson JL(2005). The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. CANCER RES vol. 65, (22) 10355-10362.
10.1158/0008-5472.CAN-05-0957
Hagemann T, Balkwill F(2005). MIFed about cancer?. GASTROENTEROLOGY vol. 129, (5) 1785-1787.
10.1053/j.gastro.2005.09.039
Madhusudan S, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, Hoare S, Balkwill F et al.(2005). Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. J Clin Oncol vol. 23, (25) 5950-5959.
10.1200/JCO.2005.04.127
Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T et al.(2005). Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol vol. 175, (2) 1197-1205.
10.4049/jimmunol.175.2.1197
Barton C, Davies D, Balkwill F, Burke F(2005). Involvement of both intrinsic and extrinsic pathways in IFN-gamma-induced apoptosis that are enhanced with cisplatin. Eur J Cancer vol. 41, (10) 1474-1486.
10.1016/j.ejca.2005.03.022
Balkwill F(2005). The language of life: How cells communicate in health and disease. NATURE vol. 435, (7046) 1162-1162.
10.1038/4351162a
Strauss S, Maharaj L, Hoare S, Trehu E, Boral A, Schenkein D, Johnson P, Balkwill F et al. (2005). Bortezomib (VELCADE (R)) in patients with relapsed/refractory lymphoma: Potential correlation of TNF alpha response and in vitro sensitivity with clinical activity. ANNALS OF ONCOLOGY. vol. 16, 65-65.
Balkwill F(2005). Immunology for the next generation. Nat Rev Immunol vol. 5, (6) 509-512.
10.1038/nri1628
Direkze N, Jeffery R, Hodivala-Dilke K, Burke F, Hunt T, Poulsom R, Alison M, Balkwill F et al. (2005). Bone marrow contributes functionally active cell types to tumour stroma. GASTROENTEROLOGY. vol. 128, A182-A182.
Direkze NC, Jeffery R, Hodivala-Dilke K, Burke F, Hunt FT, Poulsom R, Alison MR, Balkwill F et al. (2005). Bone marrow contributes to functionally active cells in tumour stroma. GUT. vol. 54, A24-A24.
Balkwill F, Watt F(2005). Fran Balkwill. J Cell Sci vol. 118, (Pt 7) 1339-1340.
10.1242/jcs.01688
Balkwill F, Charles KA, Mantovani A(2005). Smoldering and polarized inflammation in the initiation and promotion of malignant disease. CANCER CELL vol. 7, (3) 211-217.
10.1016/j.ccr.2005.02.013
Oppenheim J, Blankenstein T, Brennan F, Gordon S, Mantovani A, Strieter RM, Cerundolo V, Forni G et al. (2004). Discussion. Novartis Foundation Symposium. vol. 256, 210-214.
D'Incalci M, Strieter RM, Mantovani A, Balkwill F, Ristimäki A, Pepper MS, Gordon S, Pollard JW (2004). Final general discussion. Novartis Foundation Symposium. vol. 256, 259-265.
Smyth J, Rollins B, Harris A, Richmond A, Oppenheim J, Feldmann M, Ristimäki A, Pepper MS et al. (2004). General discussion I. Novartis Foundation Symposium. vol. 256, 49-52.
Balkwill FR (2004). The inflammatory cytokine network and the development of epithelial cancer. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION. vol. 13, 1958S-1958S.
Madhusudan S, Foster M, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, Hoare S et al.(2004). A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin Cancer Res vol. 10, (19) 6528-6534.
10.1158/1078-0432.CCR-04-0730
Balkwill F, Coussens LM(2004). Cancer - An inflammatory link. NATURE vol. 431, (7007) 405-406.
10.1038/431405a
Hagemann T, Robinson SC, Schulz M, Trümper L, Balkwill FR, Binder C(2004). Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis vol. 25, (8) 1543-1549.
10.1093/carcin/bgh146
Jones PH, Christodoulos K, Dobbs N, Thavasu P, Balkwill F, Blann AD, Caine GJ, Kumar S et al.(2004). Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer. Br J Cancer vol. 91, (1) 30-36.
10.1038/sj.bjc.6601897
Li NF, Wilbanks G, Balkwill F, Jacobs IJ, Dafou D, Gayther SA(2004). A modified medium that significantly improves the growth of human normal ovarian surface epithelial (OSE) cells in vitro. Lab Invest vol. 84, (7) 923-931.
10.1038/labinvest.3700093
Balkwill F(2004). Cancer and the chemokine network. NAT REV CANCER vol. 4, (7) 540-550.
10.1038/nrc1388
Li N, Wilbanks G, Dafou D, Jacobs I, Balkwill F, Gayther S (2004). Establishing cellular model for studying the carcinogenesis of human ovarian epithelium. BRITISH JOURNAL OF CANCER. vol. 91, S74-S74.
Szlosarek PW, Grimshaw MJ, Wilbanks GD, Burke F, Wilson JL, Balkwill FR (2004). Regulation and expression of argininosuccinate synthetase in human ovarian cancer. BRITISH JOURNAL OF CANCER. vol. 91, S57-S57.
Kulbe H, Wilson JL, Balkwill FR (2004). Transfection of the chemokine receptor CXCR4 alters the behavior of ovarian cancer cells in vitro and in vivo. BRITISH JOURNAL OF CANCER. vol. 91, S74-S74.
Balkwill F(2004). The significance of cancer cell expression of the chemokine receptor CXCR4. SEMIN CANCER BIOL vol. 14, (3) 171-179.
10.1016/j.semcancer.2003.10.003
Grimshaw MJ, Hagemann T, Ayhan A, Gillett CE, Binder C, Balkwill FR(2004). A role for endothelin-2 and its receptors in breast tumor cell invasion. Cancer Res vol. 64, (7) 2461-2468.
10.1158/0008-5472.CAN-03-1069
Arnott CH, Scott KA, Moore RJ, Robinson SC, Thompson RG, Balkwill FR(2004). Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development. Oncogene vol. 23, (10) 1902-1910.
10.1038/sj.onc.1207317
Balkwill F, Bast RC, Berek J, Chenevix-Trench G, Gore M, Hamilton T, Jacobs I, Mills G et al.(2004). Current research and treatment for epithelial ovarian cancer. A position paper from the Helene Harris Memorial Trust (vol 39, pg 1818, 2003). EUR J CANCER vol. 40, (4) 628-628.
10.1016/j.ejca.2003.11.005
Kulbe H, Levinson NR, Balkwill F, Wilson JL(2004). The chemokine network in cancer - much more than directing cell movement. INT J DEV BIOL vol. 48, (5-6) 489-496.
10.1387/ijdb.041814hk
Szlosarek P, Balkwill F(2004). The inflammatory cytokine network of epithelial cancer: therapeutic implications. Novartis Found Symp vol. 256, 227-237.
Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AEI, Balkwill FR(2003). A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res vol. 63, (23) 8360-8365.
Madhusudan S, Braybrooke JP, Forster M, Wilner S, Han C, Kaur K, Balkwill F, Hoare S et al. (2003). A phase II Trial of etanercept a recombinant human soluble tumour necrosis factor receptor (p75) fusion protein in patients with metastatic breast cancer. CLINICAL CANCER RESEARCH. vol. 9, 6192S-6192S.
Arnott CH, Scott KA, Moore RJ, Robinson SC, Thompson RG, East N, Balkwill FR (2003). Expression of both TNFR1 and TNFR2 is essential for optimal TNF-alpha-mediated skin tumor development. CLINICAL CANCER RESEARCH. vol. 9, 6212S-6212S.
Balkwill F (2003). Inhibiting inflammatory cytokines and chemokines in the tumour microenvironment. JOURNAL OF IMMUNOTHERAPY. vol. 26, S26-S27.
Madhusudan S, Protheroe A, Propper D, Han C, Corrie P, Earl H, Hancock B, Vasey P et al.(2003). A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer. BRIT J CANCER vol. 89, (8) 1418-1422.
10.1038/sj.bjc.6601321
Balkwill F, Bast RC, Berek J, Chenevix-Trench G, Gore M, Hamilton T, Jacobs I, Mills G et al.(2003). Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust. Eur J Cancer vol. 39, (13) 1818-1827.
10.1016/s0959-8049(03)00511-2
Szlosarek PW, Balkwill FR(2003). Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol vol. 4, (9) 565-573.
10.1016/s1470-2045(03)01196-3
Ramalingam S, Hoare S, Madhusudan S, Braybrooke J, Kaur K, Willner S, Harris AL, Balkwill F et al. (2003). A phase II trial of etanercept, a tumour necrosis factor-alpha inhibitor in recurrent ovarian cancer. BRITISH JOURNAL OF CANCER. vol. 88, S57-S57.
Wall L, Burke F, Barton C, Smyth J, Balkwill F(2003). IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro. Clin Cancer Res vol. 9, (7) 2487-2496.
Wall L, Burke F, Barton C, Smyth J, Balkwill F(2003). IFN-γ induces apoptosis in ovarian cancer cells in vivo and in vitro. Clinical Cancer Research vol. 9, (7) 2487-2496.
Scott KA, Moore RJ, Arnott CH, East N, Thompson RG, Scallon BJ, Shealy DJ, Balkwill FR(2003). An anti-tumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors. Mol Cancer Ther vol. 2, (5) 445-451.
Karagiannis SN, Wang Q, East N, Burke F, Riffard S, Bracher MG, Thompson RG, Durham SR et al.(2003). Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. EUR J IMMUNOL vol. 33, (4) 1030-1040.
10.1002/eji.200323185
Balkwill F(2003). Chemokine biology in cancer. SEMIN IMMUNOL vol. 15, (1) 49-55.
10.1016/S1044-5323(02)00127-6
Balkwill F, Schlom J, Berek J, Epenetos A, Bookman M, Freedman R, Wilbanks G (2003). Discussion: Immunological therapeutics in ovarian cancer. GYNECOLOGIC ONCOLOGY. vol. 88, S110-S113.
10.1002/gyno.2002.6696
Propper DJ, Chao D, Braybrooke JP, Bahl P, Thavasu P, Balkwill F, Turley H, Dobbs N et al.(2003). Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma. CLIN CANCER RES vol. 9, (1) 84-92.
Wall L, Burke F, Smyth JF, Balkwill F (2003). The anti-proliferative activity of interferon-gamma on ovarian cancer: In vitro and in vivo. GYNECOLOGIC ONCOLOGY. vol. 88, S149-S151.
10.1006/gyno.2002.6707
Wall L, Burke F, Smyth JF, Balkwill F(2003). The anti-proliferative activity of interferon-gamma on ovarian cancer: in vitro and in vivo. Gynecologic oncology vol. 88, (1 Pt 2)
Grimshaw MJ, Naylor S, Balkwill FR(2002). Endothelin-2 is a hypoxia-induced autocrine survival factor for breast tumor cells. Mol Cancer Ther vol. 1, (14) 1273-1281.
Ganesan T, Madhusudan S, Braybrooke J, Echeta C, Wilner S, Harris AL, Hoare S, Balkwill F (2002). A phase II trial of etanercept, a tumour necrosis factor-a inhibitor in recurrent ovarian cancer. EUROPEAN JOURNAL OF CANCER. vol. 38, S140-S140.
Scotton CJ, Wilson JL, Scott K, Stamp G, Wilbanks GD, Fricker S, Bridger G, Balkwill FR(2002). Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. CANCER RES vol. 62, (20) 5930-5938.
Grimshaw MJ, Wilson JL, Balkwill FR(2002). Endothelin-2 is a macrophage chemoattractant: Implications for macrophage distribution in tumors. European Journal of Immunology vol. 32, (9) 2393-2400.
10.1002/1521-4141(200209)32:9<2393::AID-IMMU2393>3.0.CO;2-4
Grimshaw MJ, Wilson JL, Balkwill FR(2002). Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumors. EUR J IMMUNOL vol. 32, (9) 2393-2400.
10.1002/1521-4141(200209)32:9<2393::AID-IMMU2393>3.0.CO;2-4
Arnott CH, Scott KA, Moore RJ, Hewer A, Phillips DH, Parker P, Balkwill FR, Owens DM(2002). Tumour necrosis factor-alpha mediates tumour promotion via a PKC alpha- and AP-1-dependent pathway. Oncogene vol. 21, (31) 4728-4738.
10.1038/sj.onc.1205588
Forster MD, Braybrooke J, Madhusudan S, Kaur K, Hoare S, Balkwill F, Ganesan TS, Talbot D et al.(2002). A phase II trial using etanercept, a recombinant tumour necrosis factor antagonist, in metastatic breast cancer. BRIT J CANCER vol. 86, S38-S38.
Wall L, Burke F, Smyth J, Balkwill F(2002). Characterisation of the cell content of malignant ascites in advanced epithelial ovarian cancer and clinico-pathological correlations. BRIT J CANCER vol. 86, S45-S46.
Milliken D, Scotton C, Raju S, Balkwill F, Wilson J(2002). Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. CLIN CANCER RES vol. 8, (4) 1108-1114.
Wilson J, Balkwill F(2002). The role of cytokines in the epithelial cancer microenvironment. SEMIN CANCER BIOL vol. 12, (2) 113-120.
10.1006/scbi.2001.0419
Balkwill F(2002). Tumor necrosis factor or tumor promoting factor?. Cytokine Growth Factor Rev vol. 13, (2) 135-141.
10.1016/S1359-6101(01)00020-X
Robinson SC, Scott KA, Balkwill FR(2002). Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-α. European Journal of Immunology vol. 32, (2) 404-412.
10.1002/1521-4141(200202)32:2<404::AID-IMMU404>3.0.CO;2-X
Robinson SC, Scott KA, Balkwill FR(2002). Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-alpha. Eur J Immunol vol. 32, (2) 404-412.
10.1002/1521-4141(200202)32:2<404::AID-IMMU404>3.0.CO;2-X
Balkwill F(2001). The science book. NATURE vol. 414, (6866) 849-850.
10.1038/414849a
Scotton C, Milliken D, Wilson J, Raju S, Balkwill F(2001). Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumours. Br J Cancer vol. 85, (6) 891-897.
10.1054/bjoc.2001.2020
Scotton CJ, Wilson JL, Milliken D, Stamp G, Balkwill FR(2001). Epithelial cancer cell migration: a role for chemokine receptors?. Cancer Res vol. 61, (13) 4961-4965.
Grimsha MJ, Balkwill FR(2001). Inhibition of monocyte and macrophage chemotaxis by hypoxia and inflammation - A potential mechanism. BRIT J CANCER vol. 85, 19-19.
Grimshaw MJ, Balkwill FR(2001). Inhibition of monocyte and macrophage chemotaxis by hypoxia and inflammation - A potential mechanism. European Journal of Immunology vol. 31, (2) 480-489.
10.1002/1521-4141(200102)31:2<480::AID-IMMU480>3.0.CO;2-L
Propper DJ, McDonald AC, Man A, Thavasu P, Balkwill F, Braybrooke JP, Caponigro F, Graf P et al.(2001). Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol vol. 19, (5) 1485-1492.
10.1200/JCO.2001.19.5.1485
Balkwill F, Mantovani A(2001). Inflammation and cancer: back to Virchow?. LANCET vol. 357, (9255) 539-545.
10.1016/S0140-6736(00)04046-0
Grimshaw MJ, Balkwill FR(2001). Inhibition of monocyte and macrophage chemotaxis by hypoxia and inflammation - a potential mechanism. EUR J IMMUNOL vol. 31, (2) 480-489.
10.1002/1521-4141(200102)31:2<480::AID-IMMU480gt;3.0.CO;2-L
Jankowski JA, Harrison RF, Perry I, Balkwill F, Tselepis C(2000). Barrett's metaplasia. LANCET vol. 356, (9247) 2079-2085.
10.1016/S0140-6736(00)03411-5
Scott KA, Holdsworth H, Balkwill FR, Dias S(2000). Exploiting changes in the tumour microenvironment with sequential cytokine and matrix metalloprotease inhibitor treatment in a murine breast cancer model. BRITISH JOURNAL OF CANCER vol. 83, (11) 1538-1543.
10.1054/bjoc.2000.1487
Sica A, Saccani A, Bottazzi B, Bernasconi S, Allavena P, Gaetano B, Fei P, LaRosa G et al.(2000). Defective expression of the monocyte chemotactic protein-1 receptor CCR2 in macrophages associated with human ovarian carcinoma. JOURNAL OF IMMUNOLOGY vol. 164, (2) 733-738.
10.4049/jimmunol.164.2.733
Balkwill FR(2000). Re: Possible role of ovarian epithelial inflammation in ovarian cancer. Journal of the National Cancer Institute vol. 92, (2) 162-163.
10.1093/jnci/92.2.162a
Balkwill F, Foxwell B, Brennan F (2000). TNF is here to stay!. Immunology Today. vol. 21, 470-471.
10.1016/S0167-5699(00)01722-9
Thavasu P, Propper D, McDonald A, Dobbs N, Ganesan T, Talbot D, Braybrook J, Caponigro F et al.(1999). The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients. Cancer research vol. 59, (16) 3980-3984.
Turner L, Scotton C, Negus R, Balkwill F(1999). Hypoxia inhibits macrophage migration. European Journal of Immunology vol. 29, (7) 2280-2287.
10.1002/(SICI)1521-4141(199907)29:07<2280::AID-IMMU2280>3.0.CO;2-C
Turner L, Scotton C, Negus R, Balkwill F(1999). Hypoxia inhibits macrophage migration. Eur J Immunol vol. 29, (7) 2280-2287.
10.1002/(SICI)1521-4141(199907)29:07<2280::AID-IMMU2280>3.0.CO;2-C
Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, Holdsworth H, Turner L et al.(1999). Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis. Nature Medicine vol. 5, (7) 828-831.
10.1038/10552
Burke F, Smith PD, Crompton MR, Upton C, Balkwill FR(1999). Cytotoxic response of ovarian cancer cell lines to IFN-γ is associated with sustained induction of IRF-1 and p21 mRNA. British Journal of Cancer vol. 80, (8) 1236-1244.
10.1038/sj.bjc.6690491
Boyd RS, Balkwill FR(1999). MMP-2 release and activation in ovarian carcinoma: The role of fibroblasts. British Journal of Cancer vol. 80, (3-4) 315-321.
10.1038/sj.bjc.6690357
Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, Holdsworth H, Turner L et al.(1999). Erratum: Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis (Nature Medicine (1999) 5 (828-831)). Nature Medicine vol. 5, (9)
Balkwill F(1999). TNF biosynthesis in gut associated immunopathologies. Gut vol. 45, (4)
10.1136/gut.45.4.483
Dias S, Boyd R, Balkwill F(1998). IL-12 regulates VEGF and MMPs in a murine breast cancer model. International Journal of Cancer vol. 78, (3) 361-365.
10.1002/(SICI)1097-0215(19981029)78:3<361::AID-IJC17>3.0.CO;2-9
Dias S, Boyd R, Balkwill F(1998). IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int J Cancer vol. 78, (3) 361-365.
10.1002/(SICI)1097-0215(19981029)78:3<361::AID-IJC17>3.0.CO;2-9
Negus RPM, Turner L, Burke F, Balkwill FR(1998). Hypoxia down-regulates MCP-1 expression: implications for macrophage distribution in tumors. JOURNAL OF LEUKOCYTE BIOLOGY vol. 63, (6) 758-765.
10.1002/jlb.63.6.758
Dias S, Thomas H, Balkwill F(1998). Multiple molecular and cellular changes associated with tumour stasis and regression during IL-12 therapy of a murine breast cancer model. International Journal of Cancer vol. 75, (1) 151-157.
10.1002/(SICI)1097-0215(19980105)75:1<151::AID-IJC23>3.0.CO;2-I
Dias S, Thomas H, Balkwill F(1998). Multiple molecular and cellular changes associated with tumour stasis and regression during IL-12 therapy of a murine breast cancer model. Int J Cancer vol. 75, (1) 151-157.
10.1002/(sici)1097-0215(19980105)75:1<151::aid-ijc23>3.0.co;2-i
Leber TM, Balkwill FR(1998). Regulation of monocyte MMP-9 production by TNF-α and a tumour-derived soluble factor (MMPSF). British Journal of Cancer vol. 78, (6) 724-732.
10.1038/bjc.1998.568
Balkwill F(1998). The molecular and cellular biology of the chemokines. J Viral Hepat vol. 5, (1) 1-14.
10.1046/j.1365-2893.1998.00081.x
(1998). United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). British journal of cancer vol. 77, (1) 1-10.
10.1038/bjc.1998.1
Leber TM, Balkwill FR(1997). Zymography: a single-step staining method for quantitation of proteolytic activity on substrate gels. Anal Biochem vol. 249, (1) 24-28.
10.1006/abio.1997.2170
Burke F, East N, Upton C, Patel K, Balkwill FR(1997). Interferon gamma induces cell cycle arrest and apoptosis in a model of ovarian cancer: Enhancement of effect by batimastat. European Journal of Cancer vol. 33, (7) 1114-1121.
10.1016/s0959-8049(97)88065-3
Negus RPM, Stamp GWH, Hadley J, Balkwill FR(1997). Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. AMERICAN JOURNAL OF PATHOLOGY vol. 150, (5) 1723-1734.
Balkwill F, Pitha PM (1997). Interferons and cytokines on a grand scale. Cytokine & Growth Factor Reviews. vol. 8, 91-95.
10.1016/s1359-6101(96)00051-2
Balkwill F(1997). Cytokine amplification and inhibition of immune and inflammatory responses. Journal of viral hepatitis vol. 4 Suppl 2, 6-15.
10.1111/j.1365-2893.1997.tb00175.x
Zucker S, Balkwill FR(1996). Correspondence re: N-B. Liabakk et al., Matrix metalloprotease 2 (MMP- 2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res., 56: 190-196, 1996. Cancer Research vol. 56, (15)
Burke F, Relf M, Negus R, Balkwill F(1996). A CYTOKINE PROFILE OF NORMAL AND MALIGNANT OVARY. Cytokine vol. 8, (7) 578-585.
10.1006/cyto.1996.0077
Burke F, Balkwill FR(1996). Cytokines in animal models of cancer. Biotherapy vol. 8, (3-4) 229-241.
10.1007/BF01877209
Balkwill FR(1996). Cytokines in Hemopoiesis, Oncology, and Immunology III. British Journal of Cancer vol. 73, (5) 711-711.
10.1038/bjc.1996.124
Thomas H, Hanby AM, Smith R-A, Hagger P, Patel K, Raikundalia B, Camplejohn RS, Balkwill FR(1996). An inbred colony of oncogene transgenic mice: diversity of tumours and potential as a therapeutic model. British Journal of Cancer vol. 73, (1) 65-72.
10.1038/bjc.1996.12
Negus RP, Balkwill FR(1996). Cytokines in tumour growth, migration and metastasis. World J Urol vol. 14, (3) 157-165.
10.1007/bf00186895
Liabakk NB, Talbot I, Smith RA, Wilkinson K, Balkwill F(1996). Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Research vol. 56, (1) 190-196.
Balkwill F(1995). Making sense. Nature vol. 378, (6554) 318-318.
10.1038/378318b0
Thomas H, Balkwill F(1995). Assessing new anti-tumour agents and strategies in oncogene transgenic mice. Cancer metastasis reviews vol. 14, (2) 91-95.
10.1007/bf00665793
Thavasu PW, Ganjoo RK, Maidment SA, Love SB, Williams AH, Malplas JS, Balkwill FR(1995). Multiple myeloma: an immunoclinical study of disease and response to treatment. Hematol Oncol vol. 13, (2) 69-82.
10.1002/hon.2900130204
de Kossodo S, Moore R, Gschmeissner S, East N, Balkwill FR(1995). Changes in endogenous cytokines, adhesion molecules and platelets during cytokine-induced tumour necrosis. British Journal of Cancer vol. 72, (5) 1165-1172.
10.1038/bjc.1995.481
Burger D, Dayer JM, Opdenakker G, Van Damme J, Mauviel A, Proost P, Van Damme J, Opdenakker G et al.(1995). Inhibitory cytokines and cytokine inhibitors. Neurology vol. 45, (6) S39-S43.
10.1212/wnl.45.6_suppl_6.s39
Burke F, Knowles RG, East N, Balkwill FR(1995). THE role of indoleamine 2,3‐dioxygenase in the anti‐tumour activity of human interferon‐γ in vivo. International Journal of Cancer vol. 60, (1) 115-122.
10.1002/ijc.2910600117
Negus RPM, Stamp GWH, Relf MG, Burke F, Malik STA, Bernasconi S, Allavena P, Sozzani S et al.(1995). The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. Journal of Clinical Investigation vol. 95, (5) 2391-2396.
10.1172/JCI117933
Balkwill F(1995). Tumour necrosis factor in ovarian cancer. Interferons and Cytokines (26) 6-8.
Balkwill FR(1994). Cytokine therapy of cancer. The importance of knowing the context. Eur Cytokine Netw vol. 5, (4) 379-385.
Naylor MS, Stamp GW, Davies BD, Balkwill FR(1994). Expression and activity of MMPS and their regulators in ovarian cancer. Int J Cancer vol. 58, (1) 50-56.
10.1002/ijc.2910580110
Miles D, Thomsen L, Balkwill F, Thavasu P, Moncada S(1994). Association between biosynthesis of nitric oxide and changes in immunological and vascular parameters in patients treated with interleukin-2. Eur J Clin Invest vol. 24, (4) 287-290.
10.1111/j.1365-2362.1994.tb01087.x
MILES DW, HAPPERFIELD LC, NAYLOR MS, BOBROW LG, RUBENS RD, BALKWILL FR(1994). EXPRESSION OF TUMOR-NECROSIS-FACTOR (TNF-ALPHA) AND ITS RECEPTORS IN BENIGN AND MALIGNANT BREAST-TISSUE. INTERNATIONAL JOURNAL OF CANCER vol. 56, (6) 777-782.
10.1002/ijc.2910560603
Thomas H, Balkwill FR(1994). Oncogene transgenic mice as therapeutic models in cancer research. Eur J Cancer vol. 30A, (4) 533-537.
10.1016/0959-8049(94)90434-0
Philip PA, Rea D, Thavasu P, Carmichael J, Stuart NS, Rockett H, Talbot DC, Ganesan T et al.(1993). Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. J Natl Cancer Inst vol. 85, (22) 1812-1818.
10.1093/jnci/85.22.1812
Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D et al.(1993). Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer research vol. 53, (22) 5365-5369.
DAVIES B, MILES DW, HAPPERFIELD LC, NAYLOR MS, BOBROW LG, RUBENS RD, BALKWILL FR(1993). ACTIVITY OF TYPE-IV COLLAGENASES IN BENIGN AND MALIGNANT BREAST DISEASE. BRITISH JOURNAL OF CANCER vol. 67, (5) 1126-1131.
10.1038/bjc.1993.207
NAYLOR MS, STAMP GWH, FOULKES WD, ECCLES D, BALKWILL FR(1993). TUMOR-NECROSIS-FACTOR AND ITS RECEPTORS IN HUMAN OVARIAN-CANCER - POTENTIAL ROLE IN DISEASE PROGRESSION. JOURNAL OF CLINICAL INVESTIGATION vol. 91, (5) 2194-2206.
10.1172/JCI116446
Balkwill F (1993). Cytokines in health and disease. Immunology Today. vol. 14, 149-150.
10.1016/0167-5699(93)90228-d
Taylor-Papadimitriou J, Balkwill F(1993). Fusion potential for vaccines. Nature vol. 362, (6422) 695-695.
10.1038/362695a0
Burke F, Naylor MS, Davies B, Balkwill F(1993). The cytokine wall chart. Immunol Today vol. 14, (4) 165-170.
10.1016/0167-5699(93)90280-x
Saraya KA, Balkwill FR(1993). Temporal sequence and cellular origin of interleukin-2 stimulated cytokine gene expression. Br J Cancer vol. 67, (3) 514-521.
10.1038/bjc.1993.96
Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR(1993). A Synthetic Matrix Metalloproteinase Inhibitor Decreases Tumor Burden and Prolongs Survival of Mice Bearing Human Ovarian Carcinoma Xenograft. Cancer Research vol. 53, (9) 2087-2091.
Balkwill F(1993). Cytokines in health and disease. Immunology Today vol. 14, (4) 149-150.
10.1016/0167-5699(93)90228-D
Balkwill F(1993). Improving on the formula. Nature vol. 361, (6409) 206-207.
10.1038/361206a0
Burke F, Stuart Naylor M, Davies B, Balkwill F(1993). The cytokine wall chart. Immunology Today vol. 14, (4)
10.1016/0167-5699(93)90280-X
Burke F, Griffin D, Elwood N, Davis C, Stamp G, Rohatiner A, Lister TA, Balkwill F(1993). The effect of cytokines on cultured mononuclear cells from patients with B cell chronic lymphocytic leukemia. Hematological oncology vol. 11, (1) 23-33.
10.1002/hon.2900110104
Balkwill F(1993). Tumour necrosis factor. Improving on the formula. Nature vol. 361, (6409) 206-207.
10.1038/361206a0
MILES DW, ADERKA D, ENGELMANN H, WALLACH D, BALKWILL FR(1992). INDUCTION OF SOLUBLE TUMOR-NECROSIS-FACTOR RECEPTORS DURING TREATMENT WITH INTERLEUKIN-2. BRITISH JOURNAL OF CANCER vol. 66, (6) 1195-1199.
10.1038/bjc.1992.435
THAVASU PW, LONGHURST S, JOEL SP, SLEVIN ML, BALKWILL FR(1992). MEASURING CYTOKINE LEVELS IN BLOOD - IMPORTANCE OF ANTICOAGULANTS, PROCESSING, AND STORAGE-CONDITIONS. JOURNAL OF IMMUNOLOGICAL METHODS vol. 153, (1-2) 115-124.
10.1016/0022-1759(92)90313-I
Naylor MS, Stamp GW, Balkwill FR(1992). Beta actin expression and organization of actin filaments in colorectal neoplasia. Epithelial cell biology vol. 1, (3) 99-104.
Malik ST, Balkwill FR(1992). Antiproliferative and antitumor activity of TNF in vitro and in vivo. Immunology series vol. 56, 239-268.
Malik TAS, East N, Boraschi D, Balkwill FR(1992). Effects of intraperitoneal recombinant interleukin-1β in intraperitoneal human ovarian cancer xenograft models: Comparison with the effects of tumour necrosis factor. British Journal of Cancer vol. 65, (5) 661-666.
10.1038/bjc.1992.141
Balkwill FR(1992). Tumour necrosis factor and cancer. Prog Growth Factor Res vol. 4, (2) 121-137.
10.1016/0955-2235(92)90027-f
Miles DW, Longhurst SJ, Harper PG, Balkwill FR(1991). Toxicity and reconstitution of recombinant interleukin-2 with albumin. The Lancet vol. 338, (8780)
10.1016/0140-6736(91)92770-3
Malik ST, Knowles RG, East N, Lando D, Stamp G, Balkwill FR(1991). Antitumor activity of gamma-interferon in ascitic and solid tumor models of human ovarian cancer. Cancer research vol. 51, (24) 6643-6649.
Thomas H, Balkwill FR(1991). Effects of interferons and other cytokines on tumors in animals: a review. Pharmacology & therapeutics vol. 52, (3) 307-330.
10.1016/0163-7258(91)90030-p
Malik S, Balkwill F(1991). Epithelial ovarian cancer: a cytokine propelled disease?. Br J Cancer vol. 64, (4) 617-620.
10.1038/bjc.1991.372
Kelly SA, Gschmeissner S, East N, Balkwill FR(1991). Enhancement of metastatic potential by gamma-interferon. Cancer Res vol. 51, (15) 4020-4027.
Stanley LA, Adams DJ, Balkwill FR, Griffin D, Wolf CR(1991). Differential effects of recombinant interferon alpha on constitutive and inducible cytochrome P450 isozymes in mouse liver. Biochem Pharmacol vol. 42, (2) 311-320.
10.1016/0006-2952(91)90718-k
MALIK STA, MARTIN D, HART I, BALKWILL F(1991). THERAPY OF HUMAN OVARIAN-CANCER XENOGRAFTS WITH INTRAPERITONEAL LIPOSOME ENCAPSULATED MURAMYL-TRIPEPTIDE PHOSPHOETHANOLAMINE (MTP-PE) AND RECOMBINANT GM-CSF. BRITISH JOURNAL OF CANCER vol. 63, (3) 399-403.
10.1038/bjc.1991.92
Lagadec PF, Saraya KA, Balkwill FR(1991). Human small‐cell lung‐cancer cells are cytokine‐resistant but NK/LAK‐sensitive. International Journal of Cancer vol. 48, (2) 311-317.
10.1002/ijc.2910480226
Naylor MS, Stamp GWH, Balkwill FR(1990). Investigation of Cytokine Gene Expression in Human Colorectal Cancer. Cancer Research vol. 50, (14) 4436-4440.
Miles DW, Bird CR, Wadhwa M, Summerhayes M, Balkwill FR, Thorpe R, Rubens RD(1990). Reconstitution of interleukin 2 with albumin for infusion. Lancet vol. 335, (8705) 1602-1603.
10.1016/0140-6736(90)91439-h
Malik STA, Stuart Naylor M, East N, Oliff A, Balkwill FR(1990). Cells secreting tumour necrosis factor show enhanced metastasis in nude mice. European Journal of Cancer and Clinical Oncology vol. 26, (10) 1031-1034.
10.1016/0277-5379(90)90044-t
Naylor MS, Malik ST, Stamp GW, Jobling T, Balkwill FR(1990). In situ detection of tumour necrosis factor in human ovarian cancer specimens. European journal of cancer (Oxford, England : 1990) vol. 26, (10) 1027-1030.
10.1016/0277-5379(90)90043-s
Malik ST, Griffin DB, Naylor MS, Fiers W, Oliff A, Balkwill FR(1990). The complex effects of recombinant tumour necrosis factor-alpha (rhTNF-alpha) in human ovarian cancer xenograft models. Prog Clin Biol Res vol. 349, 393-403.
Balkwill FR, Stuart Naylor M, Malik S(1990). Tumour necrosis factor as an anticancer agent. European Journal of Cancer and Clinical Oncology vol. 26, (5) 641-644.
10.1016/0277-5379(90)90097-d
Kelly SA, Malik STA, Balkwill FR(1989). The relevance of animal tumour models to the preclinical screening of cytokines. Cancer Surveys vol. 8, (4) 741-754.
Malik ST, Griffin DB, Fiers W, Balkwill FR(1989). Paradoxical effects of tumour necrosis factor in experimental ovarian cancer. International journal of cancer vol. 44, (5) 918-925.
10.1002/ijc.2910440529
Balkwill FR, Griffin DB, Lee AE(1989). Interferons alpha and gamma differ in their ability to cause tumour stasis and regression in vivo. Eur J Cancer Clin Oncol vol. 25, (10) 1481-1486.
10.1016/0277-5379(89)90108-9
Stebbings WSL, Vinson GP, Farthing MJG, Balkwill F, Wood RFM(1989). Effect of steroid hormones on human colorectal adenocarcinoma xenografts, of known steroid-receptor status, in nude mice. Journal of Cancer Research and Clinical Oncology vol. 115, (5) 439-444.
10.1007/BF00393333
BALKWILL FR, BURKE F(1989). THE CYTOKINE NETWORK. IMMUNOLOGY TODAY vol. 10, (9) 299-303.
10.1016/0167-5699(89)90085-6
Balkwill FR(1989). INTERFERONS. The Lancet vol. 333, (8646) 1060-1063.
10.1016/S0140-6736(89)92455-0
Balkwill FR(1989). Tumour necrosis factor. Br Med Bull vol. 45, (2) 389-400.
10.1093/oxfordjournals.bmb.a072330
RAMANI P, BALKWILL FR(1989). ACTION OF RECOMBINANT ALPHA-INTERFERON AGAINST EXPERIMENTAL AND SPONTANEOUS METASTASES IN A MURINE MODEL. INTERNATIONAL JOURNAL OF CANCER vol. 43, (1) 140-146.
10.1002/ijc.2910430126
Fiers W, Balkwill FR(1989). Future prospects and problems. Cancer Surv vol. 8, (4) 921-927.
Balkwill F(1988). Cytokines--soluble factors in immune responses. Current opinion in immunology vol. 1, (2) 241-249.
10.1016/0952-7915(88)90008-8
FENTIMAN IS, BALKWILL FR, THOMAS BS, RUSSELL MJ, TODD I, BOTTAZZO GF(1988). AN AUTOIMMUNE ETIOLOGY FOR HYPOTHYROIDISM FOLLOWING INTERFERON THERAPY FOR BREAST-CANCER. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY vol. 24, (8) 1299-1303.
10.1016/0277-5379(88)90219-2
Ramani P, Balkwill FR(1988). Human interferons inhibit experimental metastases of a human melanoma cell line in nude mice. British Journal of Cancer vol. 58, (3) 350-354.
10.1038/bjc.1988.217
Malik S, Balkwill F(1988). The anti-cancer activity of tumour necrosis factor. Annales de l'Institut Pasteur. Immunology vol. 139, (3) 285-288.
Malik S, Balkwill FR(1988). Tumour necrosis factor. British Medical Journal (Clinical research ed.) vol. 296, (6631)
10.1136/bmj.296.6631.1214
Ramani P, Balkwill FR(1987). Enhanced metastases of a mouse carcinoma afterin vitro treatment with murine interferon gamma. International Journal of Cancer vol. 40, (6) 830-834.
10.1002/ijc.2910400621
Fentiman IS, Balkwill FR, Cuzick J, Hayward JL, Rubens RD(1987). A trial of human alpha interferon as an adjuvant agent in breast cancer after loco-regional recurrence. European Journal of Surgical Oncology vol. 13, (5) 425-428.
Balkwill F, Burke F, Talbot D, Tavernier J, Osborne R, Naylor S, Durbin H, Fiers W(1987). EVIDENCE FOR TUMOUR NECROSIS FACTOR/CACHECTIN PRODUCTION IN CANCER. The Lancet vol. 330, (8570) 1229-1232.
10.1016/S0140-6736(87)91850-2
Tilles JG, Balkwill F, Davilla J(1987). 2',5'-Oligoadenylate Synthetase and Interferon in Peripheral Blood after Rubella, Measles, or Mumps Live Virus Vaccine. Experimental Biology and Medicine vol. 186, (1) 70-74.
10.3181/00379727-186-42586
Adams DJ, Balkwill FR, Griffin DB, Hayes JD, Lewis AD, Wolf CR(1987). Induction and suppression of glutathione transferases by interferon in the mouse. Journal of Biological Chemistry vol. 262, (10) 4888-4892.
Balkwill FR, Ward BG, Moodie E, Fiers W(1987). Therapeutic potential of tumor necrosis factor-alpha and gamma-interferon in experimental human ovarian cancer. Cancer research vol. 47, (18) 4755-4758.
Balkwill FR, Smyth JF(1987). Interferons in cancer therapy: a reappraisal. Lancet (London, England) vol. 2, (8554) 317-319.
10.1016/s0140-6736(87)90901-9
Dealtry GB, Naylor MS, Fiers W, Balkwill FR(1987). The effect of recombinant human tumour necrosis factor on growth and macromolecular synthesis of human epithelial cells. Experimental cell research vol. 170, (2) 428-438.
10.1016/0014-4827(87)90318-1
Dealtry GB, Naylor MS, Fiers W, Balkwill FR(1987). DNA fragmentation and cytotoxicity caused by tumor necrosis factor is enhanced by interferon-gamma. European journal of immunology vol. 17, (5) 689-693.
10.1002/eji.1830170517
Ward BG, Wallace K, Shepherd JH, Balkwill FR(1987). Intraperitoneal xenografts of human epithelial ovarian cancer in nude mice. Cancer research vol. 47, (10) 2662-2667.
Balkwill FR, Stevens MH, Griffin DB, Thomas JA, Bodmer JG(1987). Interferon gamma regulates HLA-D expression on solid tumors in vivo. Eur J Cancer Clin Oncol vol. 23, (1) 101-106.
10.1016/0277-5379(87)90426-3
Smyth JF, Balkwill FR, Cavalli F, Kimchi A, Mattson K, Niederle NE, Spiegel RJ(1987). Interferons in oncology: Current status and future directions. European Journal of Cancer and Clinical Oncology vol. 23, (6) 887-889.
10.1016/0277-5379(87)90298-7
ROWLINSON G, BALKWILL F, SNOOK D, HOOKER G, EPENETOS AA(1986). ENHANCEMENT BY GAMMA-INTERFERON OF INVIVO TUMOR RADIOLOCALIZATION BY A MONOCLONAL-ANTIBODY AGAINST HLA-DR ANTIGEN. CANCER RESEARCH vol. 46, (12) 6413-6417.
Balkwill FR(1986). Interferons: From molecular biology to man. Part 3. Interferons and disease. Microbiological Sciences vol. 3, (9) 281-284.
CARMICHAEL J, FERGUSSON RJ, WOLF CR, BALKWILL FR, SMYTH JF(1986). AUGMENTATION OF CYTOTOXICITY OF CHEMOTHERAPY BY HUMAN ALPHA-INTERFERONS IN HUMAN NON-SMALL CELL LUNG-CANCER XENOGRAFTS. CANCER RESEARCH vol. 46, (10) 4916-4920.
Balkwill FR, Proietti E(1986). Effects of mouse interferon on human tumour xenografts in the nude mouse host. International journal of cancer vol. 38, (3) 375-380.
10.1002/ijc.2910380312
Balkwill FR(1986). Interferons: from molecular biology to man. Part 2. Interferons and cell function. Microbiol Sci vol. 3, (8) 229-233.
Balkwill FR(1986). Interferons: from molecular biology to man. Part 1. Genetics and molecular biology of the interferon system. Microbiol Sci vol. 3, (7) 212-215.
RAMANI P, HART IR, BALKWILL FR(1986). THE EFFECT OF INTERFERON ON EXPERIMENTAL METASTASES IN IMMUNOCOMPETENT AND IMMUNODEFICIENT MICE. INTERNATIONAL JOURNAL OF CANCER vol. 37, (4) 563-568.
10.1002/ijc.2910370415
Balkwill FR(1986). Animal models for investigating antitumor effects of interferon. Methods Enzymol vol. 119, 649-657.
10.1016/0076-6879(86)19087-2
Balkwill FR, Lee A, Aldam G, Moodie E, Thomas JA, Tavernier J, Fiers W(1986). Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons. Cancer Research vol. 46, (8) 3990-3993.
Taylor-Papadimitriou J, Balkwill F, Ebsworth N, Rozengurt E(1985). Antiviral and antiproliferative effects of interferons in quiescent fibroblasts are dissociable. Virology vol. 147, (2) 405-412.
10.1016/0042-6822(85)90142-4
Balkwill FR, Goldstein L, Stebbing N(1985). Differential action of six human interferons against two human carcinomas growing in nude mice. International journal of cancer vol. 35, (5) 613-617.
10.1002/ijc.2910350508
Rohatiner AZ, Prior P, Burton A, Balkwill F, Lister TA(1985). Central nervous system toxicity of interferon. Prog Exp Tumor Res vol. 29, 197-202.
10.1159/000411640
FENTIMAN IS, THOMAS BS, BALKWILL FR, RUBENS RD, HAYWARD JL(1985). PRIMARY HYPOTHYROIDISM ASSOCIATED WITH INTERFERON THERAPY OF BREAST-CANCER. LANCET vol. 1, (8438) 1166-1166.
10.1016/s0140-6736(85)92475-4
Padmanabhan N, Balkwill FR, Bodmer JG, Rubens RD(1985). Recombinant DNA human interferon alpha 2 in advanced breast cancer: A phase 2 trial. British Journal of Cancer vol. 51, (1) 55-60.
10.1038/bjc.1985.8
BYE A, BALKWILL F, BRIGDEN D, WILSON J(1985). USE OF INTERFERON IN THE MANAGEMENT OF PATIENTS WITH SUBACUTE SCLEROSING PANENCEPHALITIS. DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY vol. 27, (2) 170-175.
10.1111/j.1469-8749.1985.tb03766.x
Shearer M, Taylor-Papadimitriou J, Griffin D, Balkwill F(1984). Monoclonal antibodies that distinguish between subspecies of human interferon-alpha and that detect interferon oligomers. Journal of immunology (Baltimore, Md. : 1950) vol. 133, (6) 3096-3101.
Balkwill FR, Moodie EM(1984). Positive interactions between human interferon and cyclophosphamide or adriamycin in a human tumor model system. Cancer research vol. 44, (3) 904-908.
Borden EC, Balkwill FR(1984). Preclinical and clinical studies of interferons and interferon inducers in breast cancer. Cancer vol. 53, (3 Suppl) 783-789.
10.1002/1097-0142(19840201)53:3+<783::aid-cncr2820531329>3.0.co;2-i
Balkwill FR, Bokhon'ko AI(1984). Differential effects of pure human alpha and gamma interferons on fibroblast cell growth and the cell cycle. Experimental Cell Research vol. 155, (1) 190-197.
10.1016/0014-4827(84)90780-8
BALKWILL FR, MOWSHOWITZ S, SEILMAN SS, MOODIE EM, GRIFFIN DB, FANTES KH, WOLF CR(1984). POSITIVE INTERACTIONS BETWEEN INTERFERON AND CHEMOTHERAPY DUE TO DIRECT TUMOR-ACTION RATHER THAN EFFECTS ON HOST DRUG-METABOLIZING-ENZYMES. CANCER RESEARCH vol. 44, (11) 5249-5255.
Borden EC, Balkwill FR(1984). Preclinical and clinical studies of interferons and interferon inducers in breast cancer. Cancer vol. 53, (3 S) 783-789.
10.1002/1097-0142(19840201)53:3+<783::AID-CNCR2820531329>3.0.CO;2-I
Rohatiner AZ, Prior PF, Burton AC, Smith AT, Balkwill FR, Lister TA(1983). Central nervous system toxicity of interferon. British journal of cancer vol. 47, (3) 419-422.
10.1038/bjc.1983.63
Balkwill FR, Griffin DB, Band HA, Beverley PC(1983). Immune human lymphocytes produce an acid-labile alpha-interferon. The Journal of experimental medicine vol. 157, (3) 1059-1063.
10.1084/jem.157.3.1059
McCance DJ, Sebesteny A, Griffin BE, Balkwill F, Tilly R, Gregson NA(1983). A paralytic disease in nude mice associated with polyoma virus infection. Journal of General Virology vol. 64, (1) 57-67.
10.1099/0022-1317-64-1-57
BALKWILL FR, MOODIE EM, FREEDMAN V, LANE EB, FANTES KH(1983). An Animal Model System for Investigating the AntiTumor Effects of Human Interferon. Journal of Interferon Research vol. 3, (3) 319-326.
10.1089/jir.1983.3.319
ROHATINER AZS, BALKWILL FR, MALPAS JS, LISTER TA(1983). EXPERIENCE WITH HUMAN-LYMPHOBLASTOID INTERFERON IN ACUTE MYELOGENOUS LEUKEMIA (AML). CANCER CHEMOTHERAPY AND PHARMACOLOGY vol. 11, (1) 56-58.
10.1007/bf00257419
Rohatiner AZ, Balkwill F, Lister TA(1983). Interferon in acute myelogenous leukaemia: a preliminary report. Haematology and blood transfusion vol. 28, 56-58.
10.1007/978-3-642-68761-7_11
Rohatiner AZS, Balkwill FR, Griffin DB, Malpas JS, Lister TA(1982). A phase I study of human lymphoblastoid interferon administered by continuous intravenous infusion. Cancer Chemotherapy and Pharmacology vol. 9, (2) 97-102.
10.1007/BF00265387
Taylor-Papadimitriou J, Shearer M, Balkwill FR, Fantes KH(1982). Effects of HuIFN-α2 and HuIFN-α (Namalwa) on Breast Cancer Cells Grown in Culture and as Xenografts in the Nude Mouse. Journal of Interferon Research vol. 2, (4) 479-491.
10.1089/jir.1982.2.479
Balkwill FR, Moodie EM, Freedman V, Fantes KH(1982). Human interferon inhibits the growth of established human breast tumours in the nude mouse. International Journal of Cancer vol. 30, (2) 231-235.
10.1002/ijc.2910300217
TAYLORPAPADIMITRIOU J, BALKWILL FR(1982). IMPLICATIONS FOR CLINICAL-APPLICATION OF NEW DEVELOPMENTS IN INTERFERON RESEARCH. BIOCHIMICA ET BIOPHYSICA ACTA vol. 695, (1) 49-67.
10.1016/0304-419X(82)90006-3
SILVERMAN RH, WATLING D, BALKWILL FR, TROWSDALE J, KERR IM(1982). The ppp(A2′p)<inf>n</inf>A and Protein Kinase Systems in Wild‐Type and Interferon‐Resistant Daudi Cells. European Journal of Biochemistry vol. 126, (2) 333-341.
10.1111/j.1432-1033.1982.tb06783.x
Balkwill FH(1981). Extracts from the last century. Mechanical dentistry--on regulation cases by F.H. Balkwill. British Dental Journal vol. 151, (1) 19-19.
10.1038/sj.bdj.4804620
Rohatiner A, Balkwill F, Malpas JS, Lister TA(1981). A phase I study of human lymphoblastoid interferon in patients with hematological malignancies. Haematol Blood Transfus vol. 26, 63-67.
10.1007/978-3-642-67984-1_9
Rohatiner AZS, Balkwill F, Malpas JS, Lister TA(1981). A phase I study of intravenous human lymphoblastoid interferon (HLBI). Proceedings of the American Association for Cancer Research vol. Vol. 22,
HOGG N, BALKWILL FR(1981). SPECIES RESTRICTION IN CYTOSTATIC ACTIVITY OF HUMAN AND MURINE MONOCYTES AND MACROPHAGES. IMMUNOLOGY vol. 43, (1) 197-204.
Sebesteny A, Tilly R, Balkwill F, Trevan D(1980). Demyelination and wasting associated with polyomavirus infection in nude (nu/nu) mice. Laboratory animals vol. 14, (4) 337-345.
10.1258/002367780781071021
Balkwill F, Taylor-Papadimitriou J, Fantes KH, Sebesteny A(1980). HUMAN LYMPHOBLASTOID INTERFERON CAN INHIBIT THE GROWTH OF HUMAN BREAST CANCER XENOGRAFTS IN ATHYMIC [NUDE] MICE. Annals of the New York Academy of Sciences vol. 350, (1 Regulatory Fu) 591-592.
10.1111/j.1749-6632.1980.tb20671.x
Balkwill F, Taylor-Papadimitriou J, Fantes KH, Sebesteny A(1980). Human lymphoblastoid interferon can inhibit the growth of human breast cancer xenografts in athymic (nude) mice. Eur J Cancer vol. 16, (4) 569-573.
10.1016/0014-2964(80)90237-6
Balkwill FR, Oliver RT(1979). Remission in acute myeloblastic leukaemia. Lancet vol. 2, (8149) 961-962.
10.1016/s0140-6736(79)92658-8
Balkwill FR, Hogg N(1979). Characterization of human breast milk macrophages cytostatic for human cell lines. J Immunol vol. 123, (4) 1451-1456.
Balkwill FR(1979). Interferons as cell-regulatory molecules. Cancer Immunology Immunotherapy vol. 7, (1) 7-14.
10.1007/BF00205403
Balkwill F, Taylor-Papadimitriou J(1978). Interferon affects both G<inf>1</inf> and S+G<inf>2</inf> in cells stimulated from quiescence to growth. Nature vol. 274, (5673) 798-800.
10.1038/274798a0
Balkwill F, Watling D, Taylor-Papadimitriou J(1978). Inhibition by lymphoblastoid interferon of growth of cells derived from the human breast. Int J Cancer vol. 22, (3) 258-265.
10.1002/ijc.2910220307
Balkwill FR, Oliver RT(1977). Growth inhibitory effects of interferon on normal and malignant human haemopoietic cells. International journal of cancer vol. 20, (4) 500-505.
10.1002/ijc.2910200405
Franks CR, Bishop D, Balkwill FR, Oliver RT, Spector WG(1977). Growth of acute myeloid leukaemia as discrete subcutaneous tumours in immune-deprived mice. Br J Cancer vol. 35, (5) 697-700.
10.1038/bjc.1977.107
Balkwill FR, Franks CR, Oliver RTD, Spector WG(1977). Neoplastic macrophages grown from human leukaemic monocytes. The Journal of Pathology vol. 122, (1) 13-26.
10.1002/path.1711220104
Balkwill FR, Oliver RT(1976). Diagnostic and prognostic significance of peripheral blood cultural characteristics in adult acute leukaemia. Br J Cancer vol. 33, (4) 400-410.
10.1038/bjc.1976.65
Balkwill FR, Oliver RT(1976). Morphological characterisation of adult acute leukaemia in short-term liquid culture. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer (56) 87-90.
10.1007/978-3-642-81049-7_12
Balkwill F, Pindar A, Crowther D(1974). Factors influencing microculture of leukaemia cells. Nature vol. 251, (5477) 741-742.
10.1038/251741a0
Return to top